Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Nabriva Therapeutics plc
| Metric | Nabriva Therapeutics plc Healthcare |
|---|---|
| Quality Score | 50 / 100 |
| Revenue (latest) | $37M |
| Net income (latest) | −$57M |
| Operating margin | −150.2% |
| Net margin | −154.8% |
| Return on equity | −1736.6% |
| Return on assets | −180.0% |
| Return on capital (ROCE) | −1333.9% |
| Debt / equity | 8.65× |
| Revenue growth (YoY) | 27.8% |
| Altman Z″ (distress) | -77.90 |
| Accruals / assets | −64.5% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.